ABSTRACT: Structure-based drug design (SBDD) has become a powerful tool utilised by medicinal chemists to rationally guide the drug discovery process. Herein, we describe the use of SPROUT, a de novo-based program, to identify an indazole-based pharmacophore for the inhibition of fibroblast growth factor receptor (FGFR) kinases, which are validated targets for cancer therapy. Hit identification using SPROUT yielded 6-phenylindole as a small fragment predicted to bind to FGFR1. With the aid of docking models, several modifications to the indole were made to optimise the fragment to an indazole-containing pharmacophore, leading to a library of compounds containing 23 derivatives. Biological evaluation revealed that these indazole-containing fragments inhibited FGFR1-3 in the range of 0.8-90 M with excellent ligand efficiencies of 0.30-0.48. Some compounds exhibited moderate selectivity towards individual FGFRs, indicating that further optimisation using SBDD may lead to potent and selective inhibitors of the FGFR family.
FGFRs are a sub-family of tyrosine kinases (TKs) that are involved in many cellular processes such as cell proliferation, cellular repair and cell migration. 1 Aberrant signalling within this class of kinase has many implications in cancer and particularly in bladder cancer. 2 It has been shown that around 50% of upperand lower-urinary tract tumours possess FGFR3 mutations. 3 As well as mutations within FGFR3, overexpression in both CH5183284 is a potent and selective inhibitor of FGFR1-3 exhibiting IC50 values of 9.3, 7.6 and 22 nM 7 respectively and this compound is currently under clinical investigation for the treatment of cancer patients that harbour FGFR genetic alterations.
CH5183284 was discovered using the conventional approach of high throughput screening (HTS). As a prominent approach in lead discovery, HTS allows rapid screening of large compound libraries but is limited to the chemical diversity of that library.
Typically, an HTS library may contain approximately one million compounds; a fraction of the total theoretical 'drug-like' chemical space which is predicted to be between 10 60 -10 100 compounds. 8 SBDD is a useful addition tool for lead identification that can be used alone or in conjunction with HTS to initiate and facilitate a drug discovery program. The application of SBDD can take a number of different forms such as the use of virtual HTS, template matching, and de novo molecular design.
A de novo approach can produce compounds 'from scratch'.
They are predicted to bind to a target and in theory, access limitless untapped chemical space that may not be present in current compound libraries. De novo design was first used in the 1980s with numerous programs offering access to novel chemical entities from which a number of pharmacologically active molecules have resulted. 9, 10, 11 One such program, SPROUT, was developed by Johnson et al in the early 90s and is designed for constrained structure generation. 12 Structure generation can be simplified into two steps: the first part is formation of a molecular 'skeleton' that must satisfy the steric constraints of a binding pocket; the second part is generation of a molecule(s)
by atom-substitution to the skeleton. 13 The constraints of the binding pocket are usually defined using the X-ray crystal data of a target. However, if X-ray crystal data is unavailable, it is possible to design novel inhibitors based purely on a pharmacophore hypothesis. 13 Once the constraints have been defined it is possible to choose interaction sites within the protein e.g. readily allow us to test the initial design hypotheses (Figure 3) .
Compounds 1-6 were readily prepared using classic Suzuki chemistry using available aryl bromides and boronic acids (SI-1.1).
Biological Evaluation
Compounds 1-6 were screened against FGFR1 at an initial concentration of 500 µM using a fluorescence resonance energy transfer (FRET)-based Z'-lyte ® assay 16 (SI-3.1). IC50 measurements for compounds 1-6 were determined using a 10-point titration experiment with 3-fold serial dilutions starting from a concentration of 500 µM. The results are outlined ( Table 1) optimisation. 18 Compound 6 is the most active with an IC50 value of 36 µM. Compound 4 is more active than compound 5
suggesting that the pyridine nitrogen has a detrimental effect upon the binding affinity of these fragments to FGFR1. Rationalization of these observed activities was investigated using docking models (SI-4.2).
Library Expansion
In order to expand the structure activity relationships (SARs)
for the active indazole pharmacophore 7, a larger focus library of target compounds was developed. Compounds were readily synthesised using the conditions outlined in SI-1.1 and subjected to biological evaluation ( Table 2) .
The results obtained for single point analyses were carried out at a concentration of 100 µM. The observed activities for com- 
SAR Exploration of Compounds 10 and 11
Compounds 10 and 11 were taken forward to further optimise focusing on substitution around the phenyl ring. Based on modelling (SI-4.2) it became apparent that further substitution of small hydrophobic groups in addition to the existing substituent on the 6-position phenyl ring could result in tighter binding to FGFR1. A further library was therefore developed, synthesised using the conditions outlined in SI-1.1, and biologically evaluated ( Table 3) . Compounds 21-24 were synthesised using an alternative route (SI-1.1.1). In addition to FGFR1, the activity of these compounds against FGFR2/3 was also evaluated. Inspection of the data in Table 3 reveals some interesting points. In addition to FGFR1, compound 10 was also found to inhibit hypothesise that structural expansion of these molecules will result in an increase in the small selectivity difference between FGFR1/2 that compounds 10 and 18 currently exhibit.
Conclusion
We have identified an indazole-based pharmacophore that shows encouraging levels of inhibition against FGFR kinases using a de novo-based design approach to identify the initial hit.
Optimisation of this hit led to a library of fragments whereby SARs were established and specific structural aspects of the molecules upon which sub-type selectivity appear to depend, have been identified. Current efforts are focused on designing Table 3 : Biological results for compounds 10-24 when screened against FGFR1-3.
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larger compounds in order to increase potency and, more importantly, selectivity for the individual FGFR sub-types.
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